PARP7-IN-16

Cat. No.:	HY-156419
CAS No.:	2435657-10-4
Molecular Formula:	$C_{25}H_{26}FN_4NaO_4$
Molecular Weight:	488.49
Target:	PARP
Pathway:	Cell Cycle/DNA Damage; Epigenetics
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.



SOLVENT & SOLUBILITY

In Vitro

DMSO : 100 mg/mL (204.71 mM; Need ultrasonic)

Preparing Stock Solutions	Solvent / Mass / Concentration	1 mg	5 mg	10 mg
	1 mM	2.0471 mL	10.2356 mL	20.4712 mL
	5 mM	0.4094 mL	2.0471 mL	4.0942 mL
	10 mM	0.2047 mL	1.0236 mL	2.0471 mL

Please refer to the solubility information to select the appropriate solvent.

In Vivo

1. Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline
   Solubility: ≥ 2.5 mg/mL (5.12 mM); Clear solution
2. Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline)
   Solubility: ≥ 2.5 mg/mL (5.12 mM); Clear solution
3. Add each solvent one by one: 10% DMSO >> 90% corn oil
   Solubility: ≥ 2.5 mg/mL (5.12 mM); Clear solution

BIOLOGICAL ACTIVITY

Description

PARP7-IN-16 (compound 36) is a potent, selective and orally active inhibitor of PARP-1/2/7, with IC_{50}s of 0.94, 0.87 and 0.21 nM, respectively. PARP7-IN-16 can be used for the research of breast cancer and prostate cancer[1].

IC_{50} & Target			
	PARP-1 0.94 nM (IC_{50})	PARP-2 0.87 nM (IC_{50})	PARP-7 0.21 nM (IC_{50})

REFERENCES

[1]. Zhou J, et, al. Discovery of Quinazoline-2,4(1 H,3 H)-dione Derivatives Containing a Piperizinone Moiety as Potent PARP-1/2 Inhibitors：Design, Synthesis, In Vivo Antitumor Activity, and X-ray Crystal Structure Analysis. J Med Chem. 2023 Oct 26;66(20):14095-14115.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898 Fax: 609-228-5909 E-mail: tech@MedChemExpress.com
Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA